I can extract side effects

Haishi, the headquarters of Xinmei Pharmaceutical Group.

As one of the top ten pharmaceutical groups in China, Xinmei has a number of pharmaceutical patents and a number of best-selling drugs. Recently, it has caused a sensation on the Internet because of the million-dollar anti-cancer needle.

At the same time, they will also cooperate with top foreign pharmaceutical companies, such as exchanging and licensing patented technologies, or selling each other's drugs as agents.

Today, chairman Wu Shiji sat in the spacious and bright Jiangjing meeting room and signed a patent licensing agreement for cardiovascular drugs with Pfizer.

Cardiovascular drugs are Pfizer's flagship products. This iterative new drug was launched in Eagle Country last year and has achieved remarkable curative effects and has been greatly sought after by the market.

While Xinmei introduced this drug, it also wanted to reach a series of cooperation with Pfizer in the field of anti-tumor drugs.

After all, Pfizer has a brilliant record in anti-cancer targeted drugs, and it has targeted drugs and immune drugs for lung cancer, blood cancer and other cancers.

Xinmei has recently developed a new drug for lymphoma and is actively deploying overseas markets. The in-depth cooperation with Pfizer, the first pharmaceutical company in the universe, is naturally imperative.

President Wu signed a contract with Dr. Andre, President of Pfizer Asia Pacific, and had an in-depth exchange of cooperation on anticancer drugs. Both parties are very satisfied.

Mr. Wu decided to express the enthusiasm of his host: "Dr. Andre, we will not return tonight without getting drunk."

Andre is a tall, blond, typical Westerner with a warm smile on his face.

He held Mr. Wu's hand and said in fluent Chinese: "Thank you very much for Mr. Wu's hospitality and look forward to our future cooperation."

"However," he then shook his head, with a very regretful expression on his face: "I'm going to the nearby Kunming City tomorrow to attend a press conference of a local pharmaceutical company, and I have to go there tonight."

Mr. Wu froze when he heard the name of the place in Kunming, and he forced a smile and asked, "Is it a pharmaceutical company called Sanqing?"

Andre nodded and smiled: "Yes, that pharmaceutical company announced that it has developed a broad-spectrum anti-cancer drug. It is said that it will be effective in three days. I want to see the test data."

Mr. Wu was taken aback. The anti-cancer drug from Sanqing Pharmaceutical actually alarmed the Asia-Pacific president of Pfizer?

Does Pfizer have any ideas for this cancer drug?

He looked at the assistant calmly: "Is the press conference of Sanqing Pharmaceutical tomorrow?"

The assistant replied respectfully: "That's right, it will be tomorrow morning, and they sent invitations specially before."

Mr. Wu nodded to Andre and said, "Well, Dr. Andre, I'm going to participate too, why don't we go there together."

Andre also said very happily: "That's great, we can continue to talk about cooperation on the way."

He suddenly smiled meaningfully: "We may meet many old friends at the venue tomorrow morning."

Mr. Wu was shocked. Could it be that other pharmaceutical giants are interested in Sanqing's anticancer drugs?

Suddenly his mind was jolted, and an idea flashed through. Andre came here from the imperial capital this time, and the time was so close to the press conference. Could it be that the main goal was Sanqing, not the cooperation agreement with him, Mr. Wu?

Thinking about it this way, the joy of signing the agreement suddenly disappeared completely, and Mr. Wu was in a bad mood.

So he inquired about the other party's purpose for attending the press conference.

It's a pity that Andre kept his mouth shut, and he didn't talk about Sanqing Pharmaceutical. He just chatted with Mr. Wu about some interesting things about domestic life.

Mr. Wu returned without success, so he had to give up.

At nine o'clock the next morning, Mr. Wu and Andre arrived at the headquarters of Sanqing Pharmaceuticals early.

As soon as I arrived at the gate, I saw that the parking lot was full of cars, and there was a long queue behind, and the roadside near the gate was full of cars.

The two got out of the car with their assistant and registered at the door. As soon as they arrived at the door of the administrative building, they saw Sun Chengren walking over with a happy face.

"Mr. Wu, Dr. Andre, thank you very much for coming, please come inside."

Mr. Wu and Lao Sun have been acquainted for many years, and they are still enemies. Seeing him at this time, he suddenly remembered the overwhelming criticism of Xinmei on the Internet, and a resentment emerged in his heart, so he said strangely: "Old Sanitary is a good son, I have to come and take a good look, hehe."

Old Sun smiled and pretended he didn't hear it.

Andre was very enthusiastic towards everyone, and took the initiative to reach out to greet Lao Sun for a long time before walking into the hall with Mr. Wu.

Mr. Wu looked around the hall, the interior was grandly decorated, there were a lot of banners and flowers, many chairs were placed, and many people were already sitting on them.

At the end of the hall was a high platform with many cameras in front of it, and a group of media reporters gathered around the audience.

Mr. Wu squinted his eyes, looking for acquaintances and colleagues.

Andre next to him suddenly walked to the right, waving his hands as he walked: "Dr. Schmitz, I didn't expect you to come too. It's been a long time."

The right side was full of people, and there were many foreigners with tall noses and deep eyes. A middle-aged man with a thick beard and hair stood up from the crowd and walked quickly towards Andre. The two embraced warmly.

Andre was very happy to introduce Mr. Wu.

"Dear Wu, this is Merck's global president of oncology. He used to be an old colleague of mine. I never expected him to come here."

This is a bearded foreigner, wearing thick glasses, with a scholarly air, he smiled and stretched out his hand and said, "Hello, Mr. Wu, our company has a global pharmaceutical center in nearby Hangzhou. I came here on a business trip recently, and I happened to hear a A miraculous broad-spectrum anticancer drug came out, so I came to have a look."

Mr. Wu exchanged greetings with him for a while, and suddenly he remembered that the world's first broad-spectrum anti-cancer drug, Kerida, is the flagship product of Merck. Last year's sales reached tens of billions of dollars. The domestic market is fully listed, and the sales are hot.

He seemed to understand the purpose of these global pharmaceutical giants coming to take a look.

The anti-cancer drug market is indeed an unusually rich and sweet big cake. Every pharmaceutical giant is staring at it like a hungry wolf, greedily occupying every piece of territory, unwilling to retreat even a little bit, let alone the huge domestic market. market is available for development.

Generally speaking, there are many types of cancer, and most of the therapeutic drugs are targeted drugs and immune drugs, which can only be used to treat a specific cancer.

At present, targeted drugs can only cover a small number of cancers, and the remaining cancers can only be treated with broad-spectrum anticancer drugs.

However, there are only three broad-spectrum anticancer drugs in the world, namely Merck’s Coreda, Roche’s entrectinib, and larotrectinib.

Keyradar is Merck's blockbuster anti-cancer drug, which has shown gratifying curative effects in many cancers. The first battle of fame was to cure Carter, the former president of the Eagle State, who was in his 90s.

Keyruida has entered the domestic market, and the remaining two drugs are only sold abroad due to their high prices. The latest news is that a country in Southeast Asia has launched the first cheap generic drug.

Mr. Wu couldn't help but chuckled, turned his head and looked into the distance, and sure enough, he saw the people from Roche Pharmaceuticals.

Broad-spectrum anti-cancer drugs are far more universal than targeted drugs. Every launch will attract the attention of everyone in the pharmaceutical industry. This time, Sanqing has developed the first broad-spectrum anti-cancer drug in China.

Obviously, this involves a huge domestic market, which immediately attracts a pack of wolves to watch over it.

Mr. Wu looked around again, and there were more and more familiar faces, including colleagues, media, and doctors.

The more he looked, the more startled he became. Suddenly, a middle-aged man with a dignified face came into view, and he vaguely recognized him as Director Xie from the Kunming Food and Drug Administration.

Do you actually attach so much importance to Sanqing? Even the higher authorities were alarmed.

I couldn't help feeling a little sour in my heart. The last time Xinmei's anti-cancer needle development conference didn't have so many important guests.

Hmph, Xiaowei, I want to see if you are really good, or just a sensationalist.

If there is even the slightest mistake, I'll see how you end up, ha ha.

Mr. Wu muttered to himself, found his nameplate, and sat down.

After a while, the scene also fell silent.

Because, the much-anticipated new anti-cancer drug conference has finally begun.